Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma

May 2010
American Journal of Health-System Pharmacy;5/15/2010, Vol. 67 Issue 10, p793
Academic Journal
Purpose. The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed. Summary. Vorinostat is a novel histone deacetylase (HDAC) inhibitor approved for the treatment of advanced CTCL. Its primary biochemical mechanism is to correct an aberrant balance between acetylated and deacetylated histones, the proteins involved in chromatin structure and organization. Vorinostat is metabolized and excreted following glucuronidation by the uridine diphosphate glucuronosyl-transferase (UGT) enzyme system. Polymorphisms in the gene encoding for this enzyme system, UGT1A1, may be an important predictor of vorinostat toxicity and response levels in individual patients. Vorinostat is not metabolized by and does not inhibit the cytochrome P-450 isoenzyme system, and only two drug interactions have been noted with vorinostat: warfarin and valproic acid or other HDAC inhibitors. In two Phase II studies, patients with CTCL treated with oral vorinostat demonstrated significant reductions in skin lesions and decreased disease progression. The overall response rate was approximately 30%, including one complete response and a time to response of approximately 10 weeks. At the approved 400-mg, once-daily dose, vorinostat was well tolerated, with the most common grade 1 or 2 adverse events being fatigue, nausea, and diarrhea. Moresevere toxicities included thrombocytopenia, fatigue, and nausea and occurred in less than 6% of patients. Conclusion. Vorinostat, a novel HDAC inhibitor, is efficacious and well tolerated in patients with CTCL and is being investigated for its efficacy and safety in other types of cancers and as a part of combination therapy. Index terms: Anticoagulants; Anticonvulsants; Antineoplastic agents; Dosage; Drug administration; Drug interactions; Excretion; Lymphoma; Mechanism of action; Metabolism; Pharmacokinetics; Toxicity; Valproic acid; Vorinostat; Warfarin Am J Health-Syst Pharm. 2010; 67:793-7


Related Articles

  • Combination Phototherapy with a Histone Deacetylase Inhibitor and a Potent DNA-Binding Bibenzimidazole: Effects in Haematological Cell Lines. Rodd, Annabelle L.; Ververis, Katherine; Karagiannis, Tom C. // Lymphoma (2090309X);2012, p1 

    Current treatment for cutaneous T-cell lymphoma includes phototherapy, which involves either the use of narrowband ultraviolet B light or UVA in combination with a psoralen photosensitiser. Therapy typically involves administration of the photosensitiser followed by topical exposure to UVA. A...

  • Topical HDAC Inhibitor Could 'Shape' CTCL Care. Powers, Marie // BioWorld Today;4/5/2013, Vol. 24 Issue 65, p1 

    The article reports that Shape Pharmaceuticals sought to enhance its topical histone deacetylase inhibitor SHP-141 for treating cutaneous T-cell lymphoma and other inflammatory skin diseases. SHP-141 was made by Shape to treat the disease through fast delivery of drug concentrations, done by...

  • Look Out, Folotyn; Istodax Wins Accelerated Approval in PTCL. Boggs, Jennifer // BioWorld Today;6/20/2011, Vol. 22 Issue 118, p1 

    The article reports on an accelerated approval received by Celgene Corp.'s Istodax histone deacetylase inhibitor in peripheral T-cell lymphoma (PTCL) patients. The drug was compared with Allos Therapeutics Inc.'s Folotyn. According to Celgene spokesman Greg Gelssman, PTCL is a fairly sizeable...

  • Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Ning, Zhi-Qiang; Li, Zhi-Bin; Newman, Michael; Shan, Song; Wang, Xin-Hao; Pan, De-Si; Zhang, Jin; Dong, Mei; Du, Xin; Lu, Xian-Ping // Cancer Chemotherapy & Pharmacology;Apr2012, Vol. 69 Issue 4, p901 

    Purpose: Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo antitumor characteristics of the compound. Methods: Selectivity and potency of...

  • Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Bodiford, Andrew; Bodge, Megan; Talbott, Mahsa S.; Reddy, Nishitha M. // OncoTargets & Therapy;2014, Vol. 7, p1971 

    The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%-30%. There is an urgent need to optimize induction therapy...

  • Small biotech steers HDAC inhibitor to clinic. Ratner, Mark // Nature Biotechnology;Sep2014, Vol. 32 Issue 9, p853 

    The article focuses on U.S. approval of the histone deacetylase (HDAC) inhibitor Beleodaq (belinostat) in U.S. drug market for treating rare T-cell lymphomas as of September 2014. The topics discussed include market opportunity associated with possible use of HDAC inhibitors to clinic to...

  • Romidepsin Injection.  // AHFS Consumer Medication Information;Apr2017, p1 

    Romidepsin injection is used to treat cutaneous T-cell lymphoma (CTCL; a group of cancers of the immune system that first appear as skin rashes) in people who have already been treated with at least one other medication given by mouth or by injection. Romidepsin injection is in a class of...

  • FDA Grants Priority Review For ISTODAX(R) sNDA For Treatment of Progressive or Relapsed PTCL.  // Biomedical Market Newsletter;3/21/2011, p242 

    The article reports that the U.S. Food and Drug Administration (FDA) have granted priority review classification of the Istodax supplemental new drug application (sNDA) from Celgene Corp. for treatment of peripheral T-cell lymphoma (PTCL). It says that priority reviews are granted to...

  • Belinostat Injection.  // AHFS Consumer Medication Information;Apr2017, p1 

    Belinostat is used to treat peripheral T-cell lymphoma (PTCL; a form of cancer that begins in a certain type of cells in the immune system) that has not improved or that has come back after treatment with other medications. Belinostat is in a class of medications called histone deacetylase...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics